Progressive Supranuclear Palsy - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Progressive Supranuclear Palsy - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Progressive Supranuclear Palsy: Overview
Progressive supranuclear palsy (PSP) is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. The neuropathological hallmark of PSP is a biochemical alteration in the tau protein, which results in a neurodegeneration and gliosis in the basal ganglia, brainstem, prefrontal cortex and cerebellum. Signs and symptoms of the disease varies from person to person. The most frequent symptom of PSP is a loss of balance while walking. Individuals may have unexplained falls or a stiffness and awkwardness in gait. The diagnosis of PSP is based on the person’s medical history and a physical and neurological exam. Diagnostic scans such as magnetic resonance imaging may help along with other imaging tests aiming to look for brain activity in known areas of degeneration. Treatment of progressive supranuclear palsy is symptomatic and supportive. Antidepressants, such as amitriptyline, fluoxetine, and imipramine, can also help in relieving symptoms.
'Progressive Supranuclear Palsy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Progressive Supranuclear Palsy pipeline landscape is provided which includes the disease overview and Progressive Supranuclear Palsy treatment guidelines. The assessment part of the report embraces, in depth Progressive Supranuclear Palsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Progressive Supranuclear Palsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Progressive Supranuclear Palsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Progressive Supranuclear Palsy Emerging Drugs
Further product details are provided in the report……..
Progressive Supranuclear Palsy: Therapeutic Assessment
This segment of the report provides insights about the different Progressive Supranuclear Palsy drugs segregated based on following parameters that define the scope of the report, such as:
Progressive Supranuclear Palsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Progressive Supranuclear Palsy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Progressive Supranuclear Palsy drugs.
Progressive Supranuclear Palsy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Progressive Supranuclear Palsy - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Progressive Supranuclear Palsy: Overview
Progressive supranuclear palsy (PSP) is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. The neuropathological hallmark of PSP is a biochemical alteration in the tau protein, which results in a neurodegeneration and gliosis in the basal ganglia, brainstem, prefrontal cortex and cerebellum. Signs and symptoms of the disease varies from person to person. The most frequent symptom of PSP is a loss of balance while walking. Individuals may have unexplained falls or a stiffness and awkwardness in gait. The diagnosis of PSP is based on the person’s medical history and a physical and neurological exam. Diagnostic scans such as magnetic resonance imaging may help along with other imaging tests aiming to look for brain activity in known areas of degeneration. Treatment of progressive supranuclear palsy is symptomatic and supportive. Antidepressants, such as amitriptyline, fluoxetine, and imipramine, can also help in relieving symptoms.
'Progressive Supranuclear Palsy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Progressive Supranuclear Palsy pipeline landscape is provided which includes the disease overview and Progressive Supranuclear Palsy treatment guidelines. The assessment part of the report embraces, in depth Progressive Supranuclear Palsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Progressive Supranuclear Palsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Supranuclear Palsy R&D. The therapies under development are focused on novel approaches to treat/improve Progressive Supranuclear Palsy.
- In July 2020, UCB enters into collaboration with Roche. Under the terms of agreement, UCB enter into a world-wide, exclusive license agreement with Roche and Genentech for the global development and commercialization of UCB0107, an innovative anti-Tau antibody treatment, in Alzheimer's disease (AD).
This segment of the Progressive Supranuclear Palsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Progressive Supranuclear Palsy Emerging Drugs
- RT001: Retrotope
- Bepranemab (UCB 0107): UCB
Further product details are provided in the report……..
Progressive Supranuclear Palsy: Therapeutic Assessment
This segment of the report provides insights about the different Progressive Supranuclear Palsy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Progressive Supranuclear Palsy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Progressive Supranuclear Palsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Progressive Supranuclear Palsy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Progressive Supranuclear Palsy drugs.
Progressive Supranuclear Palsy Report Insights
- Progressive Supranuclear Palsy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Progressive Supranuclear Palsy drugs?
- How many Progressive Supranuclear Palsy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Supranuclear Palsy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Retrotope
- Woolsey Pharmaceuticals
- UCB
- Novartis Pharmaceuticals
- EmeraMed
- Aquinnah Pharmaceuticals
- DTx Pharma
- APRINOIA Therapeutics
- Arvinas
- Tau-Biologics
- AlzProtect
- RT001
- Fasudil
- Bepranemab (UCB 0107)
- NIO752
- NBMI
- TDP-43 stress granules
- MSUT2 programme
- Anti tau monoclonal antibody
- Tau-targeted PROTAC® protein degraders
- TBL-100
- Ezeprogind
Introduction
Executive Summary
Progressive Supranuclear Palsy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Progressive Supranuclear Palsy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RT001: Retrotope
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Bepranemab (UCB 0107): UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
MSUT2 programme: DTx Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Progressive Supranuclear Palsy Key Companies
Progressive Supranuclear Palsy Key Products
Progressive Supranuclear Palsy- Unmet Needs
Progressive Supranuclear Palsy- Market Drivers and Barriers
Progressive Supranuclear Palsy- Future Perspectives and Conclusion
Progressive Supranuclear Palsy Analyst Views
Progressive Supranuclear Palsy Key Companies
Appendix
Executive Summary
Progressive Supranuclear Palsy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Progressive Supranuclear Palsy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
RT001: Retrotope
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Bepranemab (UCB 0107): UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
MSUT2 programme: DTx Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Progressive Supranuclear Palsy Key Companies
Progressive Supranuclear Palsy Key Products
Progressive Supranuclear Palsy- Unmet Needs
Progressive Supranuclear Palsy- Market Drivers and Barriers
Progressive Supranuclear Palsy- Future Perspectives and Conclusion
Progressive Supranuclear Palsy Analyst Views
Progressive Supranuclear Palsy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Progressive Supranuclear Palsy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Progressive Supranuclear Palsy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Progressive Supranuclear Palsy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Progressive Supranuclear Palsy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
